Table 1. Characteristics of 171 sites and 284,740 patients included in the analyses.
| Guideline expansion to CD4 ≤ 350 | Guideline expansion to CD4 ≤ 500 | Sitesa included in both analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | Sites | Patients | Sites | Patients | |||||
| N countries | N sites | N % | N | % | N % | N | % | N (%) | |
| Overall | 22 | 171 | 145 100% | 169,717 | 100% | 152 100% | 128,552 | 100% | 126/171 (74%) |
| Region | |||||||||
| Asia-Pacific | Cambodia, Hong Kong, India, Indonesia, and Vietnam | 6 | 6 4% | 2,868 | 2% | 2 1% | 378 | <1% | 2/6 (33%) |
| Central Africa | Burundi, DRC, and Rwanda | 14 | 12 8% | 5,886 | 3% | 13 9% | 3,559 | 3% | 11/14 (79%) |
| East Africa | Kenya, Tanzania, Uganda | 50 | 36 25% | 42,804 | 25% | 46 30% | 36,856 | 29% | 32/50 (64%) |
| North America | Canada and United States | 13 | 13 9% | 7,262 | 4% | 10 7% | 6,949 | 5% | 10/13 (77%) |
| Southern Africa | Malawi, South Africa, Zambia, and Zimbabwe | 83 | 73 50% | 109,012 | 64% | 78 51% | 79,664 | 62% | 68/83 (82%) |
| South and Central America | Argentina, Brazil, Chile, Mexico, and Peru | 5 | 5 3% | 1,885 | 1% | 3 2% | 1,146 | 1% | 3/5 (60%) |
| Site setting | |||||||||
| Urban | 75 | 72 50% | 81,077 | 48% | 65 43% | 60,410 | 47% | 62/75 (83%) | |
| Rural | 57 | 42 29% | 61,200 | 36% | 52 34% | 45,690 | 36% | 37/57 (65%) | |
| Unknown | 39 | 31 21% | 27,440 | 16% | 35 23% | 22,452 | 17% | 27/39 (69%) | |
| Overall cohort characteristics (“pre” and “post” groups) | |||||||||
| Median age at enrollment (IQR) | 34 (32–35) | 33 (32–35) | |||||||
| Median % women in cohort (IQR) | 62 (60–66) | 63 (59–66) | |||||||
| Cohort characteristics at baseline (“pre” group) | |||||||||
| Median % with CD4 at enrollment (IQR) | 86 (77–92) | 67 (53–80) | |||||||
| Median CD4 at enrollment (IQR) | 223 (198–290) | 273 (243–331) | |||||||
| Median % newly ART eligible under expanded guidelines (IQR)b,c | 19 (16–23) | 12 (8–15) | |||||||
| Cohort characteristics after expansion (“post” group) | |||||||||
| Median % with CD4 at enrollment (IQR) | 80 (64–88) | 61 (37–79) | |||||||
| Median CD4 at enrollment (IQR) | 261 (230–296) | 284 (248–344) | |||||||
| Median % newly ART eligible under expanded guidelines (IQR)b,c | 19 (15–21) | 11 (8–15) | |||||||
Abbreviations: ART, antiretroviral treatment; DRC, Democratic Republic of the Congo.
a There were 13,529 patients included in both analyses (in the “post” period of the expansion to CD4 ≤ 350 analysis and the “pre” period in the expansion to CD4≤500 analysis)
b Those with unknown eligibility were included in the denominator
c Defined as patients with an enrollment CD4 count between 201 and ≤350 (in the expansion to CD4 ≤ 350 analysis) or 351 and ≤500 (in the expansion to CD4 ≤ 500 analysis).